C3L-02967
— · cohortA2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA2
- subtype
- cohortA2
- age_years
- 74.39288159
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.320
- KRAS_SIGNALING_DN+0.250
- BILE_ACID_METABOLISM+0.190
- FATTY_ACID_METABOLISM+0.170
- XENOBIOTIC_METABOLISM+0.170
- ALLOGRAFT_REJECTION+0.160
- COAGULATION+0.100
- HEME_METABOLISM+0.100
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.090
- MYOGENESIS+0.050
Top 10 suppressed
- E2F_TARGETS-0.600
- G2M_CHECKPOINT-0.570
- MYC_TARGETS_V2-0.570
- MYC_TARGETS_V1-0.550
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.520
- MITOTIC_SPINDLE-0.400
- TNFA_SIGNALING_VIA_NFKB-0.400
- MTORC1_SIGNALING-0.390
- DNA_REPAIR-0.380
- OXIDATIVE_PHOSPHORYLATION-0.360
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-97-A4M1-01A-11R-A24X-07 | — | cohortA1 | 0.864 |
| 2 | SRR1516074 | — | — | 0.863 |
| 3 | TCGA-E9-A3Q9-01A-11R-A21T-07 | — | B | 0.854 |
| 4 | TCGA-97-A4M2-01A-12R-A24X-07 | — | cohortA1 | 0.852 |
| 5 | C3L-02350 | — | cohortA1 | 0.850 |
| 6 | MDT-AP-0810 | Med | Medulloblastoma | 0.843 |
| 7 | TCGA-97-8552-01A-11R-2403-07 | — | cohortA1 | 0.841 |
| 8 | TCGA-NJ-A4YQ-01A-11R-A262-07 | — | cohortA1 | 0.836 |
| 9 | TCGA-NJ-A55O-01A-11R-A262-07 | — | cohortA2 | 0.835 |
| 10 | MNG14 | — | — | 0.827 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.320 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.250 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.190 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.170 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.170 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.160 | Idelalisib | — uncovered |
| COAGULATION | 0.100 | Binimetinib | — uncovered |
| HEME_METABOLISM | 0.100 | Temsirolimus | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.090 | Inavolisib | — uncovered |
| MYOGENESIS | 0.050 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.050 | Inavolisib | — uncovered |
| COMPLEMENT | 0.040 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.030 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.030 | Inavolisib | — uncovered |